Condition
Mucous Membrane Pemphigoid
Total Trials
6
Recruiting
2
Active
2
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 2 (2)
Trial Status
Recruiting2
Withdrawn1
Completed1
Terminated1
Unknown1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT04198740Recruiting
Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface
NCT05954416Recruiting
FARD (RaDiCo Cohort) (RaDiCo-FARD)
NCT04540133Phase 2Completed
Dexamethasone Solution and Dexamethasone in Mucolox™
NCT05263505Phase 2TerminatedPrimary
Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid
NCT03839069Not ApplicableUnknown
Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis
NCT02126020Phase 1Withdrawn
Topical Infliximab in Autoimmune Eyes With Keratoprosthesis
Showing all 6 trials